ProScan Imaging Buffalo

ProScan Imaging Buffalo Canadian doctor serving Canadians needing an MRI Scan. #1 MRI center for Canadians. MRI Center serving WNY and Ontario

New CDC study finds one in five adults ages 18–64 years and one in four ages 65 years and older who survived COVID-19 ha...
06/17/2022

New CDC study finds one in five adults ages 18–64 years and one in four ages 65 years and older who survived COVID-19 had a new condition at least 4 weeks after their COVID-19 illness that may be associated with the past illness. Regardless of age, adult COVID-19 survivors had twice the risk of developing a blood clot in the lung or a new respiratory condition.

More Americans in and out of the labor force are having trouble remembering and concentrating, a common Covid-19 aftereffect.

In late summer 2021, during the Delta wave of the coronavirus pandemic, the American Academy of Physical Medicine and Re...
06/17/2022

In late summer 2021, during the Delta wave of the coronavirus pandemic, the American Academy of Physical Medicine and Rehabilitation issued a disturbing wake-up call: According to its calculations, more than 11 million Americans were already experiencing long COVID. The academy’s dashboard has been updated daily ever since, and now pegs that number at 25 million.
Even this may be a major undercount. The dashboard calculation assumes that 30 percent of COVID patients will develop lasting symptoms, then applies that rate to the 85 million confirmed cases on the books. Many infections are not reported, though, and blood antibody tests suggest that 187 million Americans had gotten the virus by February 2022. (Many more have been infected since.) If the same proportion of chronic illness holds, the country should now have at least 56 million long-COVID patients. That’s one for every six Americans.
So much about long COVID remains mysterious: The condition is hard to study, difficult to predict, and variously defined to include a disorienting range and severity of symptoms. But the numbers above imply ubiquity—a new plait in the fabric of society. As many as 50 million Americans are lactose intolerant. A similar number have acne, allergies, hearing loss, or chronic pain. Think of all the people you know personally who experience one of these conditions.
Now consider what it would mean for a similar number to have long COVID: Instead of having blemishes, a runny nose, or soy milk in the fridge, they might have difficulty breathing, overwhelming fatigue, or deadly blood clots. Even if that 30 percent estimate is too high—even if the true rate at which people develop post-acute symptoms were more like 10 or 5 or even 2 percent, as other research suggests—the total number of patients would still be staggering, many millions nationwide.
As experts and advocates have observed, the emergence of long COVID would best be understood as a “mass disabling event” of historic proportions, with the health-care system struggling to absorb an influx of infirmity, and economic growth blunted for years to come.Indeed, if—as these numbers suggest—one in six Americans already has long COVID, then a tidal wave of suffering should be crashing down at this very moment, all around us. Yet while we know a lot about COVID’s lasting toll on individuals, through clearly documented accounts of its life-altering effects, the aggregate damage from this wave of chronic illness across the population remains largely unseen.
Why is that? A natural place to look for a mass disabling event would be in official disability claims—the applications made to the federal government in hopes of getting financial support and access to health insurance. Have those gone up in the age of long COVID?
In 2010, field offices for the Social Security Administration received close to 3 million applications for disability assistance. The number dropped off at a steady rate in the years that followed, as the population of working-age adults declined and the economy improved after the Great Recession, down to just about 2 million in 2019. Then came COVID. In 2020 and 2021, one-third of all Americans became infected with SARS-CoV-2, and a significant portion of those people developed chronic symptoms. Yet the number of applications for disability benefits did not increase. In fact, since the start of the pandemic, disability claims have dropped by 10 percent overall, a rate of decline that matches up almost exactly with the one present throughout the 2010s.

“You see absolutely no reaction at all to the COVID crisis,” Nicole Maestas, an associate professor of health-care policy at Harvard, told me. She and other economists have been looking for signs of the pandemic’s effect on disability applications. At first, they expected to see an abrupt U-turn in the number of applications after the economy buckled in March 2020—just as had happened in the aftermath of prior recessions—and then perhaps a slower, continuous rise as the toll of long COVID became apparent. But so far, the data haven’t borne this out.

That doesn’t mean that the mass disabling event never happened. Social Security field offices were closed for two years, from March 17, 2020, to April 7, 2022; as a result, all applications for disability benefits had to be done online or by phone. That alone could explain why some claims haven’t yet been filed, Maestas told me. When field offices close, potential applicants have less support available to help them complete paperwork, and some give up. Even now, with many federal offices having reopened, long-haulers may be struggling more than other applicants to navigate a bureaucratic process that lasts months. Long COVID has little historical precedent and no diagnostic test, yet patients must build up enough medical documentation to prove that they are likely to remain impaired for at least a year.

In light of all these challenges, federal disability claims could end up as a lagging indicator of long COVID’s toll, in the same way that COVID hospitalizations and deaths show up only weeks after infections surge. Yet the numbers we have so far don’t really fit that explanation. The Social Security Administration told me last week that the federal government had received a total of 28,800 disability claims since the start of the pandemic that make any mention whatsoever of the applicant having been sick with COVID. This amounts to just 1 percent of the applications received during that time, by the government’s calculation, and would represent an even tinier sliver of the total number of long-COVID cases estimated overall. When I passed along this information to Maestas, she seemed at a loss for words. After a pause, she said: “It’s just not a mass disabling event from that perspective.
”The National Health Interview Survey provides another perspective, though the population effects of long COVID are no easier to find in those data. The survey, performed annually by the federal government, measures disability rates among Americans by asking whether they have, at minimum, “a lot of difficulty” completing any of a set of basic tasks, which include concentrating, remembering, walking, and climbing stairs. The proportion of people who reported such difficulties was flat through 2021: 9.6 percent of adults were disabled in December 2019, as compared with 9.5 percent two years later. Other sources of disability data do hint—but only hint—at long COVID’s consequences. When the U.S. Bureau of Labor Statistics performs its monthly employment survey, it asks Americans a few basic questions about their physical and cognitive health, including whether they have difficulties concentrating, making decisions, walking, or running errands. By this measure, the number of people reporting such problems began to nudge upward by the middle of 2021. (Disability rates briefly appeared to decline at the start of the pandemic, when in-person interviewing went on hold.) But this increase, from about 7.5 to 8 percent of the working-age population, represents a tiny blip compared with the extrapolated number of Americans who have long COVID, and most of this new cohort is still able to work. Maestas suspects that these particular disability numbers represent the first sign of a true upswing. “As you watch them keep going up each quarter, it’s starting to look like maybe there is something going on,” she said.

The survey measures described above may be affected slightly by the pandemic’s disproportionate death toll among already disabled people. They could also only ever tell one part of the story. At best, they’ll capture a certain kind of long COVID—the sort that leads to brain fog, fatigue, and weakness, among other severe impairments in memory, concentration, and mobility. One of the overarching problems here is that long COVID has been associated with many other ailments, too, such as internal tremors, sudden heart palpitations, and severe allergic reactions. None of these issues is likely to show up in the NHIS or BLS data, let alone qualify someone for long-term financial support from the Social Security Administration.

If the “mass disabling event” plays out as tens of millions of cases of shooting nerve pain or diarrhea, for example, or even just a persistent loss of smell, then you might never see a large jump in the number of Americans who report having difficulty functioning. In that case, though, more Americans might end up seeking out their doctors for evaluations, tests, and treatments. A growing number of symptoms, overall, should lead to a growing burden, overall, on the country’s health-care system.The available data suggest that the opposite is true, at least for now. A report from Kaiser Family Foundation, released last fall, found that both outpatient and inpatient health-care spending was actually lower than projected through the first half of 2021—even accounting for millions of acutely ill COVID patients. “We have not seen pent-up demand from delayed or forgone care,” the nonprofit wrote. (This modest spending was recorded despite the fact that the proportion of Americans with health insurance increased during the first two years of the pandemic.) In February, the consulting firm McKinsey surveyed leaders from 101 hospitals around the country, who said that outpatient visits and surgeries were still below pre-pandemic levels. The pandemic’s effect on health-care workers must be contributing to this decline in volume, but it can’t account for all of it. Most patients can still snag a specialist appointment within two or three weeks, according to McKinsey’s data.

It’s possible that many long-haulers have simply given up on getting medical care, because they’ve understandably concluded that treatments don’t exist or that doctors won’t believe they're sick. (The scarcity of clinics dedicated to patients with long COVID could also be a problem.) The U.K.’s Office for National Statistics has been performing one of the world’s largest long-COVID surveys, in an effort to measure the full extent of this behind-the-scenes suffering. The study shows that, as of the beginning of May, 3 percent of that country’s residents identify as having long COVID, broadly defined as “still experiencing [any] symptoms” more than four weeks after first getting sick. (Eighty percent of the U.K. population is estimated to have been infected with the coronavirus at least once.) About two-thirds of this group—amounting to more than 1 million people—say that the condition affects their ability to perform day-to-day activities. Among the survey’s most-cited chronic symptoms are weakness, shortness of breath, difficulty concentrating, muscle aches, and headaches.

In its focus on persistent symptoms, the U.K. survey may be leaving out other, more insidious consequences of COVID. A CDC analysis, published last month, examined the medical records from hundreds of thousands of adult COVID patients, and concluded that at least one in five might experience post-illness complications. Some of these were of the familiar types (trouble breathing, muscle pain); others were of the ticking-time-bomb variety, including blood clots, kidney failure, and heart attacks. This study’s methods have been harshly criticized—people who have long COVID “deserve better, much better,” Walid Gellad, a professor of medicine at the University of Pittsburgh, told me—and the one-in-five statistic could be way too high. But if the CDC’s results are correct in substance—if various mortal dangers do increase by a significant degree after COVID—then the effects of these should also be detectable at the population level. Comparisons between individual study results and overall disease burden offer a reality check for extreme findings, Jason Abaluck, an economist and a health-policy expert at Yale, told me. “They allow you to put bounds on things.

”Where does that leave us with long COVID? The majority of Americans have already encountered the virus, many more than once. The CDC suggests that these people will, on average, experience about a 50 percent increase in their respective risks of blood clots, kidney failure, and heart attacks, as well as diabetes and asthma. Comprehensive national disease estimates will take years to compile, but provisional rates of death from heart disease, stroke, and kidney disease haven’t really budged since 2019, and the NHIS survey has shown no increase in the number of Americans with high blood pressure or asthma.

In short, here’s what we can say right now: Disability rates might be rising, but only by a little bit; the health-care system seems to be coping; deaths from post-COVID complications aren’t mounting; and the labor force is holding up. Long COVID, in other words, isn’t yet standing out amid the pandemic’s other social upheavals.

Liza Fisher has long COVID, and she shows up in the data. The 38-year-old former flight attendant and yoga instructor from Houston became ill with COVID in June 2020. Her infection led to months of hospitalizations, procedures, and rehabilitation. She now requires a team of medical specialists, and she remains severely limited in her daily activities because of neurological symptoms, fatigue, and allergic reactions. Fisher went on medical leave from work after her symptoms began, and she never returned. In December 2020, she applied for disability benefits from the Social Security Administration, and was granted them about six months later.

“Government numbers aren’t accurate, and may never be accurate,” Fisher told me. She knows of long-haulers who have applied for disability programs under better-established diagnoses, for instance, because they believed that citing long COVID wouldn’t grant them access. And she said that when national metrics don’t reflect the everyday reality of the long-COVID community, advocating for research, treatment, and support services becomes more difficult.

Frank Ziegler also has long COVID, but he hasn’t quit his job, nor has he put in a claim for any benefits. A 58-year-old lawyer from Nashville, Tennessee, Ziegler developed a mild case of COVID in January 2021. The nasal congestion he experienced was so unremarkable that he assumed at first he had a simple sinus infection. But in the course of his recovery, something about Ziegler’s appetite changed—seemingly for good. Foods he had previously loved became strangely unappetizing; he lost a significant amount of weight. Then he started noticing hand tremors, trouble breathing, and cognitive issues. A battery of medical tests came back essentially normal, but Ziegler still doesn’t feel as well as he did before catching the virus. His life has changed, but that difference might not be reflected on any government graph. “The square pegs of long-COVID patients are never going to fit into the round holes of conventional testing,” he told me.

The mix of symptoms and experiences that define long COVID suggests that no single measure, or group of measures, can illustrate the suffering of long-haulers in aggregate. A “mass disabling event” is not playing out in the data we have. That could change in the months and years to come, or else it might indicate that we’re in another kind of moment, one that leaves tens of millions of Americans feeling somewhat worse off than they were before, not so sick that they can’t hold down a job or need medical attention, but also not quite back to baseline. Call it a “mass deterioration event.”

There are a significant number of people that can’t simply move on,” Ziegler told me. “Many of them have no idea why they are feeling the way they do, and they have not been able to get any relief.” That form of epidemic—one that degrades quality of life, incrementally, for millions—is likely unfolding, even as a much smaller group of patients, including Fisher, see their lives utterly transformed by chronic illness. We don’t know how bad the long-COVID crisis will get, but for many, there’s no turning back.

Benjamin Mazer

A tidal wave of chronic illness could leave millions of people incrementally worse off.

02/15/2022

New studies offer clues about who may be more susceptible to long Covid, a term for lingering Covid-19 symptoms. WSJ breaks down the science of long Covid and t

Long term risks associated with CovidFrom very early in the pandemic, it was clear that SARS-CoV-2 can damage the heart ...
02/10/2022

Long term risks associated with Covid

From very early in the pandemic, it was clear that SARS-CoV-2 can damage the heart and blood vessels while people are acutely ill. Patients developed clots, heart inflammation, arrythmias, and heart failure.

Now, the first large study to assess cardiovascular outcomes 1 year after SARS-CoV-2 infection has demonstrated that the virus’ impact is often lasting. In an analysis of more than 11 million U.S. veterans’ health records, researchers found the risk of 20 different heart and vessel maladies was substantially increased in veterans who had COVID-19 1 year earlier, compared with those who didn’t. The risk rose with severity of initial disease and extended to every outcome the team examined, including heart attacks, arrhythmias, strokes, cardiac arrest, and more. Even people who never went to the hospital had more cardiovascular disease than those who were never infected.

The results are “stunning … worse than I expected, for sure,” says Eric Topol, a cardiologist at Scripps Research. “All of these are very serious disorders. … If anybody ever thought that COVID was like the flu this should be one of the most powerful data sets to point out it’s not.” He adds that the new study “may be the most impressive Long Covid paper we have seen to date.”

Others agree the results of the study, published in Nature Medicine on 7 February, are powerful. “In the post-COVID era, COVID might become the highest risk factor for cardiovascular outcomes,” greater than well-documented risks such as smoking and obesity, says Larisa Tereshchenko, a cardiologist and biostatistician at the Cleveland Clinic.

Researchers do not know how the virus orchestrates this long-term damage. But they think the cardiovascular risks and the constellation of symptoms collectively known as Long Covid (which include brain fog, fatigue, weakness, and loss of smell) could have common roots.

“This is clearly evidence of long-term heart and vascular damage. Similar things could be happening in the brain and other organs resulting in symptoms characteristic of Long Covid, including brain fog,” says senior author Ziyad Al-Aly, a clinical epidemiologist at Washington University in St. Louis and chief of research at the VA St Louis Health Care system.

The researchers drew on the largest set of electronic health records in the United States, at the Department of Veterans Affairs (VA). They analyzed data from nearly 154,000 people who contracted COVID-19 between March 2020 and January 2021, and who survived at least 30 days after becoming infected. They also identified two control groups: 5.6 million people who sought VA care during the pandemic but were not diagnosed with COVID-19, and 5.9 million people who sought VA care in 2017.

One limitation of the study is that the veteran population skews older, white, and male: In all three groups, about 90% of patients were men and 71% to 76% were white. Patients were in their early 60s, on average.

The researchers controlled for the possibility that the people who contracted COVID-19 were already more prone to developing cardiovascular disease. They found that “COVID is an equal opportunity offender,” Al-Aly says. “We found an increased risk of cardiovascular problems in old people and in young people, in people with diabetes and without diabetes, in people with obesity and people without obesity, in people who smoked and who never smoked.”

COVID-19 boosted the risk of all 20 cardiovascular ailments studied, including heart attacks, arrhythmias, strokes, transient ischemic attacks, heart failure, inflammatory heart disease, cardiac arrest, pulmonary embolism, and deep vein thrombosis.

For example, veterans who had had COVID-19 faced a 72% higher risk of heart failure after 12 months than those in a control group who didn’t test positive. That translated to nearly 12 more infected people per 1000 developing heart failure than those in a control group. Overall, the investigators found 45 more infected people per 1000 developed any of the 20 conditions than did uninfected controls.

Just how the virus causes long-term damage to the heart and blood vessels remains a matter of debate and active research. One possible mechanism is inflammation of the endothelial cells that line the inside of the heart and blood vessels, Al-Aly says. But the researchers also include a laundry list of potential mechanisms, including lingering damage from direct viral invasion of the heart muscle; elevated levels of proinflammatory chemical messengers called cytokines that lead to scarring of the heart; and persistent virus in sites not effectively dealt with by the immune system. “The putative mechanistic pathways are still in the realm of speculation or hypothesis,” Al-Aly says.

The authors say their findings suggest millions of COVID-19 survivors could suffer long-term consequences, straining health systems for years to come. “Governments and health systems around the world should be prepared to deal with the likely significant contribution of the COVID-19 pandemic to a rise in the burden of cardiovascular diseases,” they write in the paper.

Al-Aly adds: “What really worries me is that some of these conditions are chronic conditions that will literally scar people for a lifetime. It’s not like you wake up tomorrow and suddenly no longer have heart failure.”

Giant study shows striking rise in long-term heart and vessel disease

Healthy Body, Healthier BrainKeeping your body healthy may help your brain stay healthy too. People with one or more chr...
02/03/2022

Healthy Body, Healthier Brain

Keeping your body healthy may help your brain stay healthy too.

People with one or more chronic health conditions are more likely to report worsening or more frequent memory problems, also called subjective cognitive decline (SCD).

Chronic health conditions include diabetes, heart disease, arthritis, stroke, chronic obstructive pulmonary disease (COPD), asthma, and kidney disease. SCD is most common among adults with COPD or heart disease, or who have had a stroke.

Worsening or more frequent confusion or memory loss, combined with chronic health conditions, can make it especially hard to live independently and do everyday activities like cooking, cleaning and managing health conditions. In some cases, SCD may put people at greater risk for Alzheimer’s disease.

Brain MRI shows that adults between the ages of 40 and 69 with healthy cardiovascular systems also have healthier brains, according to research to be presented at the upcoming American Stroke Association's International Stroke Conference.

For all your MRI needs
01/20/2022

For all your MRI needs

A sports injury or trauma to cartilage around the knee, hip or shoulder joint can lead to osteoarthritis later in life—o...
11/07/2021

A sports injury or trauma to cartilage around the knee, hip or shoulder joint can lead to osteoarthritis later in life—or, worse yet, the need for a new joint. So can the wear and tear that comes with age. One day, new drugs and stem-cell therapies may stop the degeneration before it starts.

Researchers are developing new techniques to protect, repair and regrow articular cartilage, the layer of connective tissue that covers the ends of bones and enables joints to move smoothly, to stop the progression of osteoarthritis and curb the need for joint replacement surgery.

Cartilage has no blood supply or nerves and limited ability to mend itself. The loss of its shock-absorbing layer and the resulting grinding of bone on bone is at the root of many cases of joint pain and arthritis. Osteoarthritis, the most common form, affects more than 32.5 million people in the U.S. More than 754,000 knee replacements and 448,000 hip replacements took place in 2017, according to the most recent federal data, and the number is expected to rise over the next decade.

Surgery is less risky than it used to be but still comes with the potential for complications. Artificial components used to replace joints may loosen or wear out after 15 to 20 years, making them a bad option for younger patients.

"We shouldn't be waiting for osteoarthritis to develop, but stopping the whole degeneration process so patients never have to have a joint replaced," says Michael Longaker, a professor of surgery at Stanford University School of Medicine and co-director of its Institute for Stem Cell Biology and Regenerative Medicine.

Researchers are working on multiple fronts to both prevent cartilage injuries in young athletes from turning into osteoarthritis a decade or two later and to regrow cartilage in older patients once it is gone. They are programming stem cells to become cartilage cells, developing drugs to change the course of osteoarthritis, experimenting with methods to more effectively deliver new cells and compounds, and designing materials to help new cells integrate with existing tissue.

The challenges are considerable. Surgeons keep refining procedures to harvest patients' own cells to repair damaged cartilage. But no approach has successfully regenerated the quality of cartilage the body starts out with. Many clinics offer untested, unregulated stem-cell treatments for joint issues, which the Food and Drug Administration warns patients to avoid. Meanwhile, no disease-modifying drug for osteoarthritis has cleared the FDA. The agency's guidelines say that such a drug must show it not only avoids or significantly delays the complications of joint failure and the need for joint replacement, but also that it reduces the deterioration of joint function and worsening of pain.

"If we can find some compound that we can inject into the knee or hip to reduce cartilage degradation and restore normal cartilage, or both, while at the same time reducing pain, that's the holy grail," says Marc C. Hochberg, a professor at the University of Maryland School of Medicine and head of its division of rheumatology and clinical immunology.

Developing Better Drugs

Dr. Hochberg led a study of sprifermin, a new experimental growth factor that works by stimulating the cartilage cells called chondrocytes. His team gave 549 patients with knee osteoarthritis one of four different dosing regimens or a placebo. Those who received the highest dose either once or twice yearly gained articular cartilage thickness over a two-year period, compared with a placebo group that had slight cartilage loss, according to a study published in the Journal of the American Medical Association in 2019. Patients who received the highest dose had no total knee replacements in the injected knee over five years, according to a report published earlier this year, compared with 15 patients in other groups who did have replacements.

Yet sprifermin didn't significantly reduce pain. German drugmaker Merck KGaA is seeking a partner to advance the development of sprifermin.

Another injectable drug, lorecivivint, works by inhibiting proteins that contribute to inflammation, cartilage degeneration and the progression of osteoarthritis, while also prompting the development of cartilage-forming cells. Patients with moderate to severe knee osteoarthritis who received a single injection of the drug reported improved pain, function and reduced impact of their symptoms over 24 weeks, according to a study published in July in Rheumatology and Therapy. Two large new trials, which are further evaluating the impact of the drug on pain, inflammation, function and cartilage protective effects, are expected to be completed at the end of the year, says Dr. Yusuf Yazici, a rheumatologist at NYU Langone Health and the chief medical officer at Biosplice Therapeutics, which is conducting the trials.

Still, some drugs that held promise in animal studies didn't perform well in human clinical trials because the body cleared the drug from the joint before it could reach the deep layer of cartilage that contains the target cells, says Paula Hammond, head of the department of chemical engineering at the Massachusetts Institute of Technology.

To protect injured cartilage from degrading further, MIT researchers are focusing on ways to get drugs into the cartilage tissue and keep them there. They are using microscopic particles called nanocarriers to deliver IGF-1, an insulin like growth factor, to the tight mesh that holds cartilage in joints. The researchers designed the carriers to be just "sticky" enough to drive deep into the cartilage without getting stuck on outer surfaces. That could allow the IGF-1 compound to be delivered in one or a few injections "until there is full regeneration," says Dr. Hammond.

In animal studies, her team found that cartilage in injured joints treated with the nanocarrier-drug combination was much less damaged compared with cartilage in untreated joints or joints treated with the drug alone. MIT now plans studies in larger animals.

The system could be used to deliver different types of treatments, says Alan Grodzinsky, a professor of biological, mechanical and electrical engineering at MIT involved in the research. There probably won't be a magic bullet for all patients, he says, and combination therapies may be necessary.

Growing Cartilage With Stem Cells

Rather than slow cartilage loss or treat symptoms, some researchers are turning to so-called regenerative medicine, guiding stem cells to effectively regrow cartilage.

Surgeons currently use a technique called microfracture to treat damaged cartilage by drilling tiny holes in the surface of a joint, prompting the body to create new tissue. But the tissue is a type called fibrocartilage, which is more like scar tissue than natural cartilage.

"It's still better than bone rubbing against bone, but it doesn't give rise to true cartilage, and over time it degrades," says Charles K.F. Chan, an assistant professor of surgery at Stanford.

Dr. Chan discovered in 2018 that skeletal stem cells at the ends of bones can give rise to cartilage, bone marrow or bone. Before turning into bone, the cells go through a cartilage stage. In experiments with the microfracture technique in mice, Dr. Chan and his team found a way to steer the development of cells toward cartilage and away from fibrocartilage. They used a powerful molecule called bone morphogenetic protein 2 to encourage skeletal stem cells to start bone formation. Then they stopped the process at the cartilage stage with a molecule called VEGF that blocks another molecule important for bone formation.

The result, says Dr. Chan, is a cartilage made of the same cells as natural cartilage, with comparable strength and function—which also restored mobility to mice with osteoarthritis and significantly reduced their pain. To prove it might work in humans, the researchers demonstrated the same process on human skeletal stem cells transferred into mice. Doctors could use the technique to boost cartilage before patients have a problem, Stanford's Dr. Longaker says. The team is now trying the approach in larger animals.

Researchers at the University of Southern California are testing a different approach.

They embedded cartilage-forming cells—derived from the pluripotent stem cells that can become any kind of cell in the body—in a collagen membrane. Using surgical glue, they implanted it like a patch on a cartilage injury in a miniature pig. The cells integrated into the host tissue and stayed there for six months, repairing damage and becoming indistinguishable from the host cartilage with a cocktail of growth factors.

Denis Evseenko, associate professor of orthopedic surgery at USC's Keck School of Medicine, whose lab led the research, says the aim is to prevent a cartilage injury in a relatively healthy joint from developing into osteoarthritis and eventually requiring a joint replacement. Dr. Evseenko says his team is manufacturing 64 implants, called Plurocart, for the first human trials, set to start in 2024.

Improving Existing Methods

Until new stem cell therapies and disease-modifying drugs are shown to be safe and effective in humans, surgeons continue to refine the current techniques to repair cartilage.

Surgeons are also working to make joint replacements more effective, as many patients report pain, stiffness and mobility issues after operations. Drugs approved for rheumatoid arthritis and new stem-cell therapies may help overcome stiffness and inflammation after joint surgery.

Scott Rodeo, an orthopedic surgeon and co-director of a soft tissue research program at New York's Hospital for Special Surgery, is testing whether injecting cells derived from human umbilical veins into the muscle and tendon of an injured rotator cuff will stimulate stem cell activity and promote better repair after surgery. The aim is to conduct a similar trial with the stem cells for cartilage repair. "If we can modulate that basic immune and inflammatory response, it may have a profound effect on tissue repair and tissue healing," Dr. Rodeo says.

With better drugs and stem-cell therapies, researchers hope to repair cartilage—or prevent damage—before osteoarthritis sets in or an operation is needed.

Address

5214 Main Street
Williamsville, NY
14221

Opening Hours

Monday 7am - 8pm
Tuesday 7am - 8pm
Wednesday 7am - 8pm
Thursday 7am - 8pm
Friday 7am - 8pm
Saturday 7am - 4pm

Telephone

+17168392600

Alerts

Be the first to know and let us send you an email when ProScan Imaging Buffalo posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to ProScan Imaging Buffalo:

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category

MRI Services for Canadians

MRI Center serving WNY and Ontario. Canadian doctor serving Canadians needing an MRI Scan. Most trusted MRI center for Canadians. MRI in Buffalo for Canadians.